title: Panobinostat for the management of multiple myeloma.
abstract: Multiple myeloma (MM) is the second most common blood cancer following non-Hodgkin's lymphoma. While the treatments for MM have improved over the past decade, for the most part, it remains an incurable disease. For this reason newer therapeutic agents are needed to combat this malignancy. Panobinostat is a pan-deacetylase inhibitor that impedes protein destruction by disturbing the enzymatic activity of deacetylases. It was US FDA approved in February 2015 for the management of relapsed/refractory MM in combination with bortezomib and dexamethasone. Several trials are ongoing, exploring the utility of panobinostat in various other settings for the management of MM. This review will detail the biology, clinical efficacy and potential future applications of panobinostat in the treatment of MM.
authors: Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
authors: Dharshan
authors: D
authors: Sivaraj
authors: Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
authors: Michael M
authors: MM
authors: Green
authors: Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
authors: Cristina
authors: C
authors: Gasparetto
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D019468:Disease Management; D004353:Drug Evaluation, Preclinical; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism; D000077767:Panobinostat; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D000077767:Panobinostat; D006655:Histone Deacetylases
keywords: HDAC inhibitor; PANORAMA; immunomodulation; induction therapy; maintenance therapy; multiple myeloma; panobinostat; plasma cell dyscrasia; relapsed/refractory; vorinostat